linjc16/ctgov huggingface dataset:
Renal Anemia Refractory to Erythropoietin

Study Overview
=================
Brief Summary
-----------------
This study evaluates the renal anemia refractory to Epo . in hemodialysis patients. all of participants will receive Epo. and identify various factors contributing to etiology of renal anemia in Epo- resistant patients.

Detailed Description
-----------------
Chronic kidney disease (CKD) is considered a public health problem worldwide with high incidence and prevalence rates.Anemia is one of the most frequent early complication of CKD. The main cause is erythropoietin (EPO) deficiency due to impaired kidney function However, other causes should be considered when the severity of anemia is inconsistent with the decrease in renal function; when there is evidence of iron deficiency or matching decreases in hemoglobin, leukopenia and/or thrombocytopenia are also found

Official Title
-----------------
Renal Anemia Refractory to Erythropoietin

Conditions
-----------------
ESRD, Renal Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients greater than or equal to 18 years old with CKD on hemodialysis Exclusion Criteria: - Evidence of infections especial of vascular access . - malnutrition and manifestation of iron, B12, folate and protein deficiency . - any underling cause as; Hematologic malignances -Hemolytic anemia - Aplastic anemia (infection and/or bleeding with anemia) Solid tumors Bleeding (skin ,mucosal ,orificial) Evidence of mineral bone disease (CKD-MBD) Others

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal anemia refractory to erythropoietin | 1 .Measurement of Hemoglobin , feritin and reitculocyte of patient before treatmeant by Epo. 100IU per Kg per week-SC. 2- Assessment to measure of hemoglobin of patient after treatment | 1 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal anemia refractory to erythropoietin | 1 .Measurement of Hemoglobin of patient by CBC before treatmeant by Epo. 100IU per Kg per week-SC? 2- Assessment to hemoglobin of anemic patient during the specified post -dose period ,6months | 6MONTHS |
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids

Study Overview
=================
Brief Summary
-----------------
Using a retrospective analysis of a large commercial claims database and a Medicare database, the investigators evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s)

Official Title
-----------------
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids

Conditions
-----------------
Chronic Low Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic low back pain Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CLBP<br> | |
| CLBP OU<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retrospective chronic low back pain
Automating Breast Radiation Therapy (RT)

Study Overview
=================
Brief Summary
-----------------
Breast radiation treatment is planned from a Computed Tomography (CT) scan. This study is designed to investigate a method to reduce the time between the planning of radiation treatment and its actual start by automating the intensity-modulated radiation therapy (IMRT) planning process. The investigators plan to examine data from another scan called Cone Beam Computed Tomography (CBCT). A CBCT scan provides similar information to a conventional CT scan, however the images for CBCT are acquired at the treatment unit (linear accelerator used for treatment). Using these x-ray pictures of patients, the study team consisting of a radiation oncologist, a medical physicist and a radiation therapist will create a custom treatment plan unique to each patient. By doing this, the investigators hope to reduce the amount of time spent waiting for treatment and the number of hospital visits for patients in the future.

Official Title
-----------------
Automating the Breast Radiation Therapy Process to Improve Efficiency

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Cone Beam CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with breast cancer who will receive standard two-field tangential whole breast radiation therapy with dose prescription of 4240 cGy in 16 fractions, 5000 cGy in 25 fractions or 4000 cGy in 16 fractions. Patients with any stage of breast cancer. Patients with prior treatment such as surgery or chemotherapy for any type of cancer. Able to provide a written informed consent. 18 years of age or older. Exclusion Criteria: < 18 years of age. Unable to provide informed consent. Males. Patients who received partial breast radiation and not the standard dose. Patients who will not receive 4240 cGy in 16 fractions, 5000 cGy in 25 fractions, or 4000 cGy in 16 fractions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cone Beam CT<br> | Procedure: Cone Beam CT<br>* Patients will also have a CBCT scan when they are having their first IMRT treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To generate on-line IMRT treatment plans using automated tools based on CBCT images acquired at the treatment unit. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CBCT, Breast Cancer
Influence of Smoking on Periodontal Healing One Year After Active Treatment

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to investigate whether cigarette smoking had any impact on the clinical outcomes 1 year after active periodontal treatment. Eligible for the study were 5680 individuals 20-85 years, referred to the specialised clinic for periodontal treatment at Gävle County Hospital between the years of 1980 and 2015. Before examination, all individuals filled in a questionnaire regarding their medical health, medication and smoking habits. Excluded were edentulous individuals and where clinical data 1-year after active treatment, or smoking habits were missing (n=1453). Complete data for analyses was available for 4227 individuals.

Official Title
-----------------
Influence of Smoking on Periodontal Healing One Year After Active Treatment

Conditions
-----------------
Smoking, Periodontal Diseases

Intervention / Treatment
-----------------
* Procedure: Healing after treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals referred to a specialist clinic for periodontal treatment Exclusion Criteria: edentulous individuals

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Healing after treatment|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Probing pocket depth | Probing pocket depth | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smoking, Periodontal treatment, Periodontal disease, Healing
Iscar for Supplemental Care in Stage IV Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Detailed Description
-----------------
See Brief Summary

Official Title
-----------------
Iscar for Supplemental Care in Stage IV Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Iscar
* Drug: mistletoe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage IV NSCLC patients who receive standard chemotherapy Exclusion criteria: Known allergy to Viscum Album L. Concomitant use of other mistletoe products Concomitant use of mushroom glucan and proteoglycan extracts Concomitant use of thymus extract products Inability to self-report quality of life utilizing assessment tools Ongoing steroid or ACTH therapy Co-morbid immunocompromised state Pregnancy Participation in other clinical trials

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Iscar|nan|
|Drug: mistletoe|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, herbal medicine, non-small cell cancer, Iscar, mistletoe
A Novel Technique to Anaesthetize the Lower Jaw

Study Overview
=================
Brief Summary
-----------------
This study introduces and evaluates a new technique for inferior alveolar nerve blocking.

Detailed Description
-----------------
The study addresses a novel technique to anaesthetize the inferior alveolar nerve depending on extraoral landmarks. Volunteers will receive bilateral blocks and evaluation of the success rate and positive aspiration rate will be performed.

Official Title
-----------------
Inferior Alveolar Nerve Block: a Novel Intraoral Technique Depends on Extraoral Landmarks

Conditions
-----------------
Inferior Alveolar Nerve Block

Intervention / Treatment
-----------------
* Procedure: A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fitness for nerve block local anaesthesia physically and psychologically Exclusion Criteria: any disease or condition obstacles nerve block local anaesthesia administration such as hemophilia.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: participants<br>participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks | Procedure: A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin<br>* blocking the inferior alveolar nerve using extroral landmarks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of numbness (by questionnaire) | evaluation of the presence of numbness in the anatomical area supplied by the inferior alveolar nerve | 3-10 minutes | 
| absence of pain (by probing) | evaluation of absence of pain in the anatomical area supplied by the inferior alveolar nerve | 3-10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| positive aspiration rate | evaluation of the presence of blood on drawing in two perpendicular planes | 1 second | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anaesthesia, Technique, extraoral, Landmarks
Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Video Assisted Thoracoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
Erector Spinae Plane Block (ESPB) is a newly described and effective interfascial plane block for thoracic and abdominal surgery. It was first described by Forero et al. in 2016, effectiveness being reported in four cases. The paravertebral block has been successfully used in various surgical patient groups for purposes of anesthesia or postoperative pain management such as thoracotomy, breast surgery and abdominal surgery. The aim of this study is to compare the analgesic effects of erector spinae plane block and paravertebral block in patients undergoing video assisted thoracoscopic surgery.

Official Title
-----------------
Erector Spinae Plane Block Versus Thoracic Paravertebral Block on Postoperative Pain for Video Assisted Thoracoscopic Surgery

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Bupivacaine Hcl 0.25% Inj


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologist's physiologic state I-III patients Undergoing video assisted thoracoscopic surgery Exclusion Criteria: chronic pain bleeding disorders renal or hepatic insufficiency patients on chronic non-steroidal anti-inflammatory medications emergency cases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ultrasound guided erector spinae plane block<br>ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine | Drug: Bupivacaine Hcl 0.25% Inj<br>* Single shot 20 ml 0.25 bupivacaine<br>|
| Active Comparator: ultrasound guided paravertebral block<br>ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine | Drug: Bupivacaine Hcl 0.25% Inj<br>* Single shot 20 ml 0.25 bupivacaine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative opioid consumption | First 24 hours total fentanyl consumption with patient controlled analgesia | First 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analog pain score | Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) | postoperative 0-24 hours | 
| Block performing time | The block time was defined as the period between the insertion of the needle and termination of local anesthetic administration | First hour |
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Official Title
-----------------
A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Conditions
-----------------
Allergic Conjunctivitis

Intervention / Treatment
-----------------
* Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
* Drug: Olopatadine Hydrochloride Ophthalmic Solution Vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model Exclusion Criteria: Under 10 years of age

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Olopatadine Hydrochloride 0.2%<br>Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks | Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%<br> <br> |
| Placebo Comparator: Vehicle<br>Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks | Drug: Olopatadine Hydrochloride Ophthalmic Solution Vehicle<br>* Inactive ingredients used as a placebo comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily ocular itching and redness scores |  | Up to Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with daily ocular itching and redness scores of 0 |  | Up to Day 14 |
Will Adjusting the pH of Lidocaine Reduce the Pain During Injection of Local Anaesthetic?

Study Overview
=================
Brief Summary
-----------------
This study will investigate the influence of adjusting the pH of lidocaine on pain during subcutaneous injection. Each participant will receive two injections on the abdomen with different pH. After each injection, the subject will be asked to evaluate the pain on a Visual analog scale (0-100 mm). It is anticipated that the pain decreases with increasing pH. The aim of the study is to find a simple method for pain reduction that can be used in clinical practice.

Official Title
-----------------
Will Adjusting the pH of Lidocaine Reduce the Pain During Injection of Local Anaesthetic?

Conditions
-----------------
Needlestick Injuries

Intervention / Treatment
-----------------
* Procedure: Lidocaine injection with bicarbonate
* Procedure: lidocaine injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fyll inn Age 18-65 years Exclusion Criteria: Kidney, heart or liver disease Eczema or psoriasis on injection site Neuropathy Regular use of painkillers Hypersensitivity of Lidocaine Pregnancy Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bicarbonate<br>Each participant will receive two lidocaine injections on the abdomen with different pH | Procedure: Lidocaine injection with bicarbonate<br>* bicarbonate added to change pH<br>Procedure: lidocaine injection<br>* Lidocaine injection with pH unchanged<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Visual Analog Scale 0-100 mm Questionnaire | 60 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain, Injections, Lidocaine, Healthy volunteers